Abstract
BackgroundImmune checkpoint blockade (ICB) using anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the treatment of advanced cancer. However, ICB is effective for only a small fraction of patients, and biomarkers such as...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have